or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Hypertrophic cardiomyopathy (HCM) is entering a phase of intense translational research
that holds promise for major advances in disease‐specific pharmacological therapy. For …

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF)
remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA–PEFF …

Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …

Background: Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophic
cardiomyopathy (HCM), is capable of producing symptoms that impact quality of life and is …

Background—The differential diagnosis of left ventricular (LV) hypertrophy remains
challenging in clinical practice, in particular, between hypertrophic cardiomyopathy (HCM) …

Background: Identification of people with hypertrophic cardiomyopathy (HCM) who are at
risk of sudden cardiac death (SCD) and require a prophylactic implantable cardioverter …

Left ventricular (LV) hypertrophy consists in an increased LV wall thickness. LV hypertrophy
can be either secondary, in response to pressure or volume overload, or primary, ie not …

Background—Youthful age has been considered the time of greatest risk for patients with
hypertrophic cardiomyopathy (HCM), largely because of the possibility of sudden death. The …

Background—Although noninvasively detected myocardial fibrosis (MF) has clinical
implications in hypertrophic cardiomyopathy, the extent, type, and distribution of ventricular …